Please assess the completion status of the following clinical trial:

Trial Title: A Study in Migraine Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are migraine patients with migraine onset before 50 years of age~* Present with diagnosis of at least 1 year with migraine attack defined by International Headache Society (IHS) guidelines~* Have a frequency of 4 to 14 migraine attacks, with or without aura, per month (with no more than 14 headache days per month, migraine or non-migraine) for at least the last 6 months~* Female patients of childbearing potential must test negative for pregnancy at the time of enrollment and agree to use a reliable method of birth control during the study~Exclusion Criteria:~* Are currently enrolled in, or discontinued within the previous 6 months from a migraine clinical trial involving an investigational drug or device or off-label use of a drug or device~* Are currently enrolled in, or discontinued within the previous 30 days from screening from a non-migraine clinical trial involving an investigational drug or device or off-label use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study~* Have previously completed or withdrawn from this study or any other study investigating LY2300559~* Have known allergies to LY2300559 or related compounds (such as montelukast)~* Are under treatment with medication or procedures for prevention of migraine, or are taking any other medications that are excluded by the protocol~* Have a history of alcohol or drug abuse/dependence within the past 3 months of screening or are currently using alcohol, drugs of abuse (including opioids, barbiturates, and marijuana), or any prescribed or over-the-counter medication in a manner that the investigator considers indicative of abuse/dependence~* Screen positive for drugs of abuse~* Patients with medication overuse headache as per IHS definition~* Have a body mass index (BMI) of less than 18.5 or greater than or equal to 35.0~* Have history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, constituting a risk when taking the study medication or interfering with the interpretation of the data~* Show evidence of serious active neuropsychiatric disease including, but not limited to, bipolar disorder, schizophrenia, psychosis, cluster B personality disorders \[for example (eg), borderline personality disorder or narcissistic personality disorder\], obsessive-compulsive disorder, or other serious mood, anxiety, depression, or substance/alcohol use disorders~* Have ever in his/her lifetime attempted suicide, have any recent suicidal ideation within the last 3 months, or are at significant risk to commit suicide, as judged by the investigator~* Show evidence or have history of neurological disease such as cerebral vascular accident, pseudotumor cerebri, multiple sclerosis, transient ischemic attack, syncopal episodes, encephalitis, or meningitis~* Have a history or seizures other than febrile~* Female patients who are pregnant or breast-feeding~* Females of childbearing potential who are not using a clinically acceptable method of birth control (eg, oral contraceptives or abstinence)~* Are unwilling or unable to comply with the use of a data collection device to directly record patient data~* Are otherwise unable to comply with the requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LY2300559 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).